Serum creatinine improved until 6 months after stopping CsA therapy. Serum creatinine did not change in the following 6 months. Therefore it is likely the patient has irreversible renal impairment due to chronic nephrotoxicity in CsA treatment. After CsA treatment permanent renal impairment may occur, especially when CsA is administered for a long time [6. 7] . Morphological changes in kidneys associated with CsA treatment suggest the probability of chronic and irreversible renal injury [7, 8] . This case report clearly shows that CsA should be used with restraint and caution until ways are found to mitigate its nephrotoxicity. CsA has been demonstrated to be nephrotoxic if the concentration is maintained at more than 300 ng/ml for extended periods [7] . Some correlation exists between a rise in serum creatinine and morphological 54 Letters to the Editor changes [8] . Therefore CsA trough level should not exceed 300 ng/ml and any rise in serum creatinine during CsA treatment should be avoided. References Van Joost T. Bos JD. Heule F. et al: Low-dose cyclosporin A in severe psoriasis. A double-blind study. Br J Dermatol 1988; 118:183-190 Incidence data for AD range from 0.7 to 2.4 depending upon the age as well as the ethnic group studied [2] . In a national screening survey performed in the US the prevalence of AD was estimated to be from 7 (adults) to 19 (children) per 1.000 [3] . In England a survey revealed a 3.1 % prevalence among children under the age of 5 [4] . As in psoriasis AD tends to become even more frequent in the northern countries of Europe [5] . Since both diseases occur at comparatively high frequencies especially in the younger age group, it would be reasonable to suspect that in a considerable number of patients both skin diseases are simultaneously present. The calculated rates of simultaneously occurrence of both diseases should amount from 0.05 to 0.30% among the Caucasian population. However, the rate of concomitance which should be statistically expected in both diseases has not yet been proven. Within a patient sample of 1,065 psoriatics attending an inpatient psoriasis clinic within half a year we found 18 (1.7%) cases with an additional diagnosis of AD confirmed by histological investigation. This finding was within the expected range. A positive history of the disease among family members could be found within 44% of all cases with psoriasis. 39% with AD and 33% with rhinitis allergica or asthma bronchiale. Besides typical psoriatic lesions and atopic eczemas (which were also examined histologically) the following marked symptoms were found in addition: pruritus within 100%; white dermographism within 89% (16 patients); a positive sign of the so-called Auspitz phenomena within 83% (15 patients); rhinitis allergica or asthma bronchiale within 72% (13 patients). In 89% of all patients (16 patients) the IgE level was increased with a geometrical mean of 888 U/ml. The HLA-Cwb was positive within 50% (9 patients). Since we focused on patients with typical and fully developed symptoms and did not include patients with minimal or mixed symptoms the frequency of concomitant forms could be supposed to be much higher. A possible explanation of the low concomitance of both diseases found until now might be that in an acute state of disease psoriatic lesions might dominate AD and makes an exact diagnosis more difficult. Itching and sebostasis as the symptoms of a therapy thought to be too 'aggressive' might represent the first signs of an additional AD. With regard to the incidence of both diseases it should be expected that a lack of concomitance should rarely be found. Therefore, in a more thorough documentation this combination should be found more frequently. 
